Theranexus (XPAR:ALTHX) ROCE % : -117.15% (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Theranexus ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Theranexus's annualized ROCE % for the quarter that ended in Dec. 2023 was -117.15%.

Theranexus ROCE % Historical Data

The historical data trend for Theranexus's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theranexus ROCE % Chart

Theranexus Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-50.73

-39.53

-62.63

-48.11

-90.37

Theranexus Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial												-65.73	-44.85	-51.05	-86.97	-117.15

Theranexus ROCE % Calculation

Theranexus's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-7.546	/	( ( (12.054 - 1.29)	+	(7.238 - 1.301) )	/ 2 )
	=	-7.546	/	( (10.764	+	5.937)	/ 2 )
	=	-7.546	/	8.3505
	=	-90.37 %

Theranexus's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-7.456	/	( ( (7.974 - 1.182)	+	(7.238 - 1.301) )	/ 2 )
	=	-7.456	/	( ( 6.792	+	5.937 )	/ 2 )
	=	-7.456	/	6.3645
	=	-117.15 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Theranexus (XPAR:ALTHX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Theranexus ROCE % Related Terms

Thank you for viewing the detailed overview of Theranexus's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Theranexus (XPAR:ALTHX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theranexus SA (XPAR:ALTHX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

3VG:Germany

Address

60 avenue Rockefeller, Pepiniere Laennec, Lyon, FRA, 69008

Website

https://www.theranexus.com

Theranexus SA is a France based biopharmaceutical company. It is engaged in developing drug candidates to be used in the treatment of central nervous system (CNS) disorders. The company's therapeutics platform is based on simultaneously targeting neurons and glial cells by creating and developing innovative combinations of two distinct drugs: a CNS drug targeting neuronal activity; and a drug targeting glial cells. The drug candidates of the organization are THN102 to treat excessive daytime sleepiness in Parkinson's disease, THN201 for the treatment of neurocognitive disorders in Alzheimer's disease and THN101 for neuropathic pain.

Theranexus (XPAR:ALTHX) Headlines

No Headlines